Characterizing the Epidemiology of Cannabidiol (CBD) Use Among US Adults

Contributed by: Eric C. Leas, PhD, MPH – Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego

Dataset Summary

This dataset contains de-identified survey data from a nationally sampled, probability-based online survey of U.S. adults conducted by Ipsos Public Affairs on behalf of the University of California San Diego in October–November 2023. Respondents were recruited from Ipsos KnowledgePanel, and the survey was administered in English and Spanish.

The final main survey file includes 2,880 screening respondents, including 1,525 qualified respondents, and 314 variables. Survey measures cover CBD use prevalence and frequency, product type, dose, mode of use, purchase source, purposes for use, health conditions, clinician recommendation, medication substitution and adjunct use, self-reported adverse events, other substance use, awareness and use of derived cannabinoid products including delta-8-THC, CBN, CBG, and HHC, microdosing of cannabis and selected psychedelic substances, self-rated physical and mental health, quality of life, demographics, geographic profile variables, and survey weights.

The dataset is intended to support research on cannabinoid product use, health behaviors, policy environments, and public health implications among U.S. adults.

Related Publications

• Satybaldiyeva N, Yang KH, Kepner W, Ferran K, Leas EC. Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults. Journal of Cannabis Research. 2025;7(1):100. doi:10.1186/s42238-025-00359-8. Full text
• Satybaldiyeva N, Yang KH, Kepner WE, Leas EC. U.S. State Marijuana and Delta-8-Tetrahydrocannabinol Laws and Delta-8-Tetrahydrocannabinol Use. American Journal of Preventive Medicine. 2025;69(6):108026. doi:10.1016/j.amepre.2025.108026. Full text
• Austin EAC, Berghammer L, Ellis SE, Appolon G, Brooks J, Rice NM, Land P, Ping S, Satybaldiyeva N, Grant I, Leas EC. Self-reported use of cannabidiol as a substitute or adjunct for approved medications. Frontiers in Public Health. 2026;14:1720348. doi:10.3389/fpubh.2026.1720348. Full text
• Yang KH, Satybaldiyeva N, Kepner W, Friedman J, Ping S, Leas EC. Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among US Adults. American Journal of Preventive Medicine. 2026;108381. doi:10.1016/j.amepre.2026.108381. Full text

OASIS: Observational Anxiety Study on Inflammation and Stress

Contributed by: University of Colorado Boulder, Institute of Cognitive Science – CU Change

Dataset Summary

This dataset was collected from 2017–2022 on adults living in the Denver/Boulder area with at least mild anxiety symptoms who were either regular cannabis users or had not used in the past 6 months. Participants were divided into four groups: 1) cannabis users randomly assigned to a THC-dominant product, 2) users randomly assigned to a balanced THC:CBD product, 3) users randomly assigned to a CBD-dominant product, and 4) non-users who served as a comparison group. Data was then collected on participants over the course of 4 weeks as they consumed their assigned legal market flower ad libitum, with measures collected on demographics, psychiatric symptoms, substance use, blood cannabinoid levels, and acute mood/drug effects before and after use of product during a mobile laboratory visit.

Top validated assessments include: AUDIT, BDI-II, MWC, MCQ, STAI, ASRS, PSS, RSRS, GAD-7, BAI, MDS, TLFB, DASS, L-CAT, DEQ, ARCI/M-Scale, Dot Probe Task, NCB, ISLT, EATS, RI, PANAS, and POMS.

Related Publications

• For an always up-to-date list of publications associated with this dataset, visit the OASIS project webpage or view publications from this study on PubMed.